News
LCTX
1.325
+0.38%
0.005
Weekly Report: what happened at LCTX last week (0629-0703)?
Weekly Report · 2d ago
Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call
Benzinga · 07/01 08:05
Weekly Report: what happened at LCTX last week (0622-0626)?
Weekly Report · 06/29 09:41
Weekly Report: what happened at LCTX last week (0615-0619)?
Weekly Report · 06/22 09:46
Weekly Report: what happened at LCTX last week (0608-0612)?
Weekly Report · 06/15 09:47
Lineage Cell Shareholders Reaffirm Governance and Executive Pay
TipRanks · 06/12 22:53
Weekly Report: what happened at LCTX last week (0601-0605)?
Weekly Report · 06/08 09:45
Weekly Report: what happened at LCTX last week (0525-0529)?
Weekly Report · 06/01 09:47
H.C. Wainwright Reaffirms Their Buy Rating on Lineage Therap (LCTX)
TipRanks · 05/26 17:49
Weekly Report: what happened at LCTX last week (0518-0522)?
Weekly Report · 05/25 09:49
Weekly Report: what happened at LCTX last week (0511-0515)?
Weekly Report · 05/18 09:49
Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Lineage Therap (LCTX) and RenovoRx (RNXT)
TipRanks · 05/15 19:30
Lineage Cell Therapeutics Q1 Earnings Call Highlights
Barchart · 05/15 18:10
Lineage Cell Therapeutics Highlights R&D Momentum Amid Losses
TipRanks · 05/14 00:12
Canaccord Genuity Reaffirms Their Buy Rating on Lineage Therap (LCTX)
TipRanks · 05/13 11:21
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), PROCEPT BioRobotics (PRCT) and Lineage Therap (LCTX)
TipRanks · 05/13 10:50
Lineage targets operations into Q2 2028 as it launches COR1 and scales ILT1 manufacturing
Seeking Alpha · 05/13 01:52
Lineage Cell Therapeutics reports Q1 EPS (3c), consensus (2c)
TipRanks · 05/12 22:11
Lineage Cell sees cash, equivalents funding operations into 2Q28
TipRanks · 05/12 22:10
Lineage Cell Therapeutics GAAP EPS of -$0.03 misses by $0.01, revenue of $1.72M misses by $1.36M
Seeking Alpha · 05/12 20:03
More
Webull provides a variety of real-time LCTX stock news. You can receive the latest news about Lineage Cell The through multiple platforms. This information may help you make smarter investment decisions.
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).